Professor Anthony Wierzbicki
Disclosure details
Site clinical trial investigator for Akcea (Volanesorsen); Regeneron (evinacumab) in Familial Chylomicronaemia Syndrome. Site trial co-investigator evolocumab in chronic coronary disease (VESALIUS).Consultant in Metabolic Medicine/Chemical Pathology at Guy’s & St. Thomas’ Hospitals, London
Honorary Professor in Cardiometabolic Disease at King’s College, London
Professor Anthony Wierzbicki is consultant in metabolic medicine/chemical pathology at Guy’s & St. Thomas’ Hospitals and honorary Professor in Cardiometabolic Disease at King’s College, London. He runs a regional centre for lipid disorders and set up the regional bariatric service. He is clinical lead for Blood Sciences at Viapath at Guy’s & St Thomas’ Hospitals. He is secretary of the national network of specialist Lipid laboratories. His research interests are in the role of lipids in atherosclerosis and in peroxisomal diseases. He is a Fellow of the American Heart Association and the National Academy of Clinical Biochemistry (USA). He has published 350 papers, 19 book chapters including for the Oxford Textbook of Medicine and Kumar & Clark’s Pathology and 1 book. He was a trustee of HEART-UK (UK Cholesterol charity) and chairman of its medical and scientific committee (2002-08).
He helped write the International guidelines on Familial Hypercholesterolaemia (2014) and the American Heart Association scientific consensus statement on Familial Hypercholesterolemia (2015). At the National Institute for Health and Clinical Excellence (NICE) he has served on the Technology Appraisal (2006-9), Highly Specialised (orphan disease) Therapies (2013-5) and Diagnostics Appraisal committees (2014-20). He was a member of the Familial Hypercholesterolaemia guideline group (CG71; 2008-2009) and chair of the Lipid Modification (CG181; 2012-4); Chronic Heart Failure (NG106; 2016-18), Hypertension (NG136; 2017-) and now Chronic Kidney Disease guidelines (CG182; 2018).
